Pdx Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PDX Pharmaceuticals is a private, preclinical-stage biotech focused on developing novel nanotherapeutics to overcome resistance and trigger immune responses in cancer. Its core asset is the versatile Pdx-NP™ platform, capable of systemic or intratumoral delivery of multiple payloads, enabling combination therapies aimed at difficult-to-treat solid tumors. The company has raised approximately $13.5 million to date, predominantly from non-dilutive government grants, and is preparing for clinical trials of its lead candidates, ARAC-02 and AIRISE-02, targeted for 2025. With a strong academic foundation, over 60 publications, and an extensive IP portfolio, PDX is positioning itself at the intersection of nanotechnology, AI-guided discovery, and immuno-oncology.

Oncology

Technology Platform

Pdx-NP™: A proprietary, silica-based nanoparticle platform for the co-delivery of multiple therapeutic cargo types (siRNA, drugs, vaccines, immunotherapies) with capabilities for both systemic (IV) and intratumoral administration to target cancer and immune cells.

Opportunities

The growing immuno-oncology market, particularly for combination therapies that can overcome resistance to checkpoint inhibitors, presents a major opportunity.

The platform's versatility allows for rapid generation of new drug candidates targeting multiple pathways and cancer types, enabling a broad pipeline from a single core technology.

Risk Factors

High preclinical-to-clinical translational risk for its novel nanotechnology platform.

Dependence on raising significant private capital to initiate costly clinical trials.

Intense competition in the nano-drug delivery and cancer immunotherapy space from larger, better-funded companies.

Competitive Landscape

PDX operates in the competitive fields of nanomedicine and immuno-oncology, competing with other nanotech delivery companies (e.g., BIND Therapeutics historically, Arrowhead Pharmaceuticals in RNA delivery) and numerous biotechs developing intratumoral immunotherapies. Its differentiation lies in its multi-cargo silica nanoparticle and strong academic/IP foundation.

More companies in Drug Delivery & Formulation →More companies in United States →